Evidence map›Paper›PMID 31981014›Full record

ArticleJournal of neuro-oncology2020

Identification of epithelial membrane protein 2 (EMP2) as a molecular marker and correlate for angiogenesis in meningioma.

Kunal S Patel, Sameer Kejriwal, Michel M Sun, Samasuk Thammachantha, Courtney Duong, Ann Chan, Nina Cherian, Prasanth Romiyo, Lynn K Gordon, William Yong and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Kunal S PatelDepartment of Neurosurgery, University of California, Los Angeles, CA, USA.
Sameer KejriwalDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA.
Michel M SunDepartment of Ophthalmology, University of California, Los Angeles, CA, USA.
Samasuk ThammachanthaDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA.
Courtney DuongDepartment of Neurosurgery, University of California, Los Angeles, CA, USA.
Ann ChanDepartment of Ophthalmology, University of California, Los Angeles, CA, USA.
Nina CherianDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA.
Prasanth RomiyoDepartment of Neurosurgery, University of California, Los Angeles, CA, USA.
Lynn K GordonDepartment of Ophthalmology, University of California, Los Angeles, CA, USA.
William YongDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA.
Madhuri WadehraDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA.
Isaac YangDepartment of Neurosurgery, University of California, Los Angeles, CA, USA. Iyang@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-5176-5615
University of California, Los Angeles · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Using EMP2 for Image Guided Drug Delivery for Breast CancerR01CA163971 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI OLAFSEN, TOVE, WADEHRA, MADHURI · 2012 to 2016
$1.6M
NCI NIH HHS P50 CA211015NCI NIH HHS P50-CA211015NCI NIH HHS R01 CA163971
6 · The paper itself

Abstract

purposeAlthough intracranial meningiomas are the most common primary brain tumor in adults, treatment options are few and have traditionally been limited to surgical resection and radiotherapy. Additional targeted therapies and biomarkers are needed, especially as complete surgical resection is frequently not feasible in many patients.

methodsNon-pathologic brain tissue from 3 patients undergoing routine autopsies and tumor specimens from 16 patients requiring surgical resection for meningioma were collected. EMP2 protein expression was evaluated by immunohistochemistry and western blot analysis. EMP2 mRNA expression was also investigated using surgical specimens and validated by analysis of several independent NCBI GEO databases.

resultsEMP2 mRNA expression levels were found to be higher in meningioma relative to non-pathologic meninges (P = 0.0013) and brain (P = 0.0011). Concordantly, strong EMP2 protein expression was demonstrated in 100% of meningioma specimens from all 16 patients, with no observable protein expression in normal brain tissue samples from 3 subjects (P < 0.001). EMP2 expression was confirmed by western blot analysis in five samples, with EMP2 protein intensity positively correlating with histologic staining score (R

conclusionsEMP2 is not found in normal brain tissue, yet has shown consistently high mRNA and protein expression in meningiomas, and may serve as a useful molecular marker for these tumors.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorFemaleHumansMaleMembrane GlycoproteinsMeningeal NeoplasmsMeningiomaMiddle AgedNeovascularization, PathologicRNA, MessengerBiomarkers, TumorEMP2 protein, humanMembrane GlycoproteinsRNA, MessengerAngiogenesisEMP-2ImmunohistochemistryMeningioma

Identifiers

PMID31981014
PMCPMC7080560
OpenAlexW3002959612

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.